Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Expression of BRAF V600E Mutant Protein in Epithelial Ovarian Tumors

Expression of BRAF V600E Mutant Protein in Epithelial Ovarian Tumors RESEARCH ARTICLE Expression of BRAF V600E Mutant Protein in Epithelial Ovarian Tumors Matthias Preusser, MD,*w David Capper, MD,zy Anna S. Berghoff, MD,*w Reinhard Horvat, MD,8 Fritz Wrba, MD,8 Monika Schindl, MD,z Sebastian F. Schoppmann, MD,# Andreas von Deimling, MD,zy and Peter Birner, MD, MScw8 approach using immunohistochemistry and genetic analysis Background: Genetic analyses have identified BRAF V600E seems advisable, as both methods lead to incorrect results in mutations in a subset of ovarian carcinomas. The aim of some cases. this study was to investigate the expression of BRAF V600E Key Words: ovarian carcinoma, BRAF, BRAF V600E, BRAF aberrant protein using a novel mutation-specific antibody in mutation, immunohistochemistry epithelial ovarian tumors. (Appl Immunohistochem Mol Morphol 2013;21:159–164) Methods: We immunohistochemically analyzed expression of V600E-mutant BRAF protein in archival formalin-fixed, par- affin-embedded tissue specimens of 142 epithelial ovarian tu- mors [98 invasive carcinomas and 44 tumors of low malignant -RAF murine sarcoma viral oncogene homolog B1 potential (LMP)] using monoclonal antibody VE1. BRAF mu- V(BRAF) is a serine/threonine kinase involved in the tation status was validated in all immunopositive cases and in 6 mitogen-activated protein kinase (MAPK) pathway. Ac- immunonegative control cases by gene sequencing. tivating mutations of BRAF, most commonly (> http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Expression of BRAF V600E Mutant Protein in Epithelial Ovarian Tumors

Loading next page...
 
/lp/wolters-kluwer-health/expression-of-braf-v600e-mutant-protein-in-epithelial-ovarian-tumors-O9VbjWIwev

References (19)

Copyright
Copyright © 2012 by Lippincott Williams & Wilkins
ISSN
1541-2016
DOI
10.1097/PAI.0b013e31825d7402
pmid
22820660
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE Expression of BRAF V600E Mutant Protein in Epithelial Ovarian Tumors Matthias Preusser, MD,*w David Capper, MD,zy Anna S. Berghoff, MD,*w Reinhard Horvat, MD,8 Fritz Wrba, MD,8 Monika Schindl, MD,z Sebastian F. Schoppmann, MD,# Andreas von Deimling, MD,zy and Peter Birner, MD, MScw8 approach using immunohistochemistry and genetic analysis Background: Genetic analyses have identified BRAF V600E seems advisable, as both methods lead to incorrect results in mutations in a subset of ovarian carcinomas. The aim of some cases. this study was to investigate the expression of BRAF V600E Key Words: ovarian carcinoma, BRAF, BRAF V600E, BRAF aberrant protein using a novel mutation-specific antibody in mutation, immunohistochemistry epithelial ovarian tumors. (Appl Immunohistochem Mol Morphol 2013;21:159–164) Methods: We immunohistochemically analyzed expression of V600E-mutant BRAF protein in archival formalin-fixed, par- affin-embedded tissue specimens of 142 epithelial ovarian tu- mors [98 invasive carcinomas and 44 tumors of low malignant -RAF murine sarcoma viral oncogene homolog B1 potential (LMP)] using monoclonal antibody VE1. BRAF mu- V(BRAF) is a serine/threonine kinase involved in the tation status was validated in all immunopositive cases and in 6 mitogen-activated protein kinase (MAPK) pathway. Ac- immunonegative control cases by gene sequencing. tivating mutations of BRAF, most commonly (>

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Mar 1, 2013

There are no references for this article.